Rare Kidney Diseases Market Growth

According to a recently published report by Roots Analysis, given the surge in demand for novel treatment options targeting rare kidney diseases, and expedited regulatory approvals of drugs, the rare kidney diseases market is anticipated to rise exponentially in the coming years.

Global Rare Kidney Diseases Market Overview

The global rare kidney diseases market is expected to reach USD 11.6 billion by 2035, growing at a CAGR of 15.2% during the forecast period till 2035. 

According to the US Centers for Disease Control and Prevention, in 2024, about 35.5 million people in the US were estimated to be suffering from kidney diseases, which accounted for approximately 14% of the overall population in the US. Rare kidney diseases are a subset of kidney disorders that affect a small fraction of people worldwide. They encompass diverse group of disorders that impair the structure and function of the kidneys, resulting in progressive damage and kidney failure. Notably, according to the Orphan Drug Act, in the United States, diseases are considered rare when they affect less than 200,000 Americans, and according to the European Union, this criteria range is around 5 per 10,000 Europeans. Notably, these conditions can be genetic, autoimmune, or associated with other systemic diseases, making their diagnosis and treating highly complex. Patients often face delayed or missed diagnoses due to the limited awareness and shared symptoms with the more common kidney disorders. Rare kidney diseases represent a significant area of unmet medical need, where the research is primarily focused on understanding disease mechanisms, identifying biomarkers, and developing targeted therapies to improve patient outcomes.

Browse 175+ figures and 170+ market data tables spread across ~320 slides and detailed Table of Content on “Global Rare Kidney Diseases Market, till 2040 by Target Disease Indication (Atypical Hemolytic Uremic Syndrome, Fabry Disease, Focal Segmental Glomerulosclerosis, Immunoglobulin A Nephropathy, Lupus Nephritis and Others), Type of Molecule (Biologics and Small Molecules), Type of Biologic (Enzymes, Hormones, Monoclonal Antibodies and Proteins), Route of Administration (Intravenous, Oral and Subcutaneous), Type of Therapy (Monotherapy and Combination Therapy), Key Geographical Regions (North America (US, Canada), Europe (France, Germany, Italy, Spain and UK), Asia-Pacific (Australia, China, India, Japan, South Korea and Taiwan)), Sales Forecast and Leading Drug Developers” here: https://www.rootsanalysis.com/reports/rare-kidney-diseases-market.html

Market Drivers

Several factors contribute to rare kidney disease market growth. The rising research activity in this domain has enabled the enhancement of developers’ comprehension towards disease pathophysiology, leading to the identification of new therapeutic targets. Further, advanced technologies, that are capable of directly examining the affected organ are actively being explored to uncover novel pathophysiological pathways, further contributing to the market’s advancement. These drivers coupled with the increasing government support for development of such drugs, are fueling the rare kidney diseases market.

Market Restraints 

Despite growing onset of patients worldwide suffering from rare kidney diseases, the development of such drugs is associated with high costs. This is primarily because these drugs require a detailed analysis of patient’s genetic makeup, which is conducted using advanced diagnostic kits. As a result, the overall cost rises, creating a barrier for small drug developers to sustain their presence in the market. Moreover, the lack of awareness and insufficient data on rare kidney diseases further impedes consistent market growth. These factors collectively act as barriers to wider adoption, challenging the market’s ability to support its growth trajectory.

Growth Factors

Despite the aforementioned restraints, several factors continue to drive the global rare kidney diseases market growth forward. One notable factor is less competition among drug developers, enabling players to investigate novel therapeutic targets that have the potential to occupy a sizeable share of this niche market. Further, the increasing incentivization associated with drug designations has significantly driven the growth of rare kidney diseases market as benefits like user-fee exemption, tax credits and grant support encourage developers to engage in more extensive research. Owing to the aforementioned factors, it can be anticipated that the global rare kidney diseases market will flourish remarkably in the foreseen future.

Global Rare Kidney Diseases Market Segments 

Based on the target disease indication, the market is segmented into Atypical Hemolytic Uremic Syndrome, Fabry Disease, Focal Segmental Glomerulosclerosis, Immunoglobulin A Nephropathy, Lupus Nephritis and Others.

• The lupus nephritis sub-segment led the global rare kidney diseases market, capturing the largest revenue share of around 30% in the current year.
• The market for other indications is anticipated to grow at a higher annualized rate of ~50%, during the forecast period.

Based on the type of molecule, the market is segmented into Biologics and Small Molecules.

• The small molecules sub-segment led the global rare kidney diseases market, capturing the largest revenue share of around 55% in the current year. 
• The market for biologics is anticipated to grow at a higher annualized rate (CAGR) during the forecast period.

Based on the type of biologic, the market is segmented into Monoclonal Antibodies, Enzymes, Proteins and Hormones.

• The monoclonal antibodies sub-segment led the global rare kidney diseases market, capturing the largest revenue share of around 85% in the current year.    
• The proteins sub-segment is anticipated to show the highest growth rate of ~30% during the forecast period.

Based on the route of administration, the market is segmented into Intravenous, Oral and Subcutaneous Routes.

• The oral route of administration led the global rare kidney diseases market, capturing the largest revenue share of around 55% in the current year.
• The market for subcutaneous route of administration is anticipated to grow at the highest CAGR of ~30% during the forecast period.

Based on the type of therapy, the market is segmented into Monotherapy and Combination Therapy.

• The monotherapy sub-segment is solely responsible for the revenues generated in the global rare kidney diseases market in the current year.
• The combination therapy sub-segment is anticipated to grow at the highest CAGR during the forecast period.

Based on the regional insights, the market is segmented into North America, Europe and Asia-Pacific.

• North America dominated the global rare kidney diseases market and accounted for the largest revenue share in the current year.
• In Asia-Pacific, the global rare kidney diseases market is anticipated to grow at the highest annualized rate during the forecast period.

Key Companies Profiled 

The global rare kidney diseases market report also includes detailed profiles of key companies (listed below) that are engaged in the rare kidney diseases domain:

• Advicenne 
• Alexion Pharmaceuticals 
• Amgen
• Asahi Kasei
• Biogen
• Boehringer Ingelheim
• Calliditas Therapeutics
• Jiangsu Hengrui Pharmaceuticals
• Novartis
• NovelMed
• Roche
• Travere Therapeutics
• Vertex Pharmaceuticals
• Vera Therapeutics
• ZyVersa Therapeutics

You Can Download Free Sample PDF Copy of This Report At: 
https://www.rootsanalysis.com/reports/rare-kidney-diseases-market/request-sample.html

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 1,500 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

Contact Details

Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com